High salt levels in common medicines put patients at increased risk of cardiovascular events

Researchers at the University of Dundee and University College London found that taking the maximum daily dose of some medicines would exceed the recommended daily limits for sodium, without any additional dietary intake.

They say the public "should be warned about the potential dangers of high from prescribed medicines" and that sodium-containing formulations "should be prescribed with caution only if the perceived benefits outweigh the risks."

They also call for the of medicines to be clearly labelled in same way as foods are labelled.

Numerous studies have shown that excess salt is harmful to heart health. Many commonly prescribed medicines have sodium added to improve their absorption into the body, but the effect of this is unknown.

The team, led by Dr Jacob George, Senior Clinical Lecturer and Honorary Consultant in Clinical Pharmacology at the University of Dundee, compared the risk of (non-fatal heart attack, non-fatal stoke, or vascular death) in patients taking sodium-containing effervescent, dispersible and soluble medications with those taking non-sodium versions of the same drugs between 1987 and 2010.

Over 1.2 million UK patients were tracked for an average of just over seven years. During this time, over 61,000 incident cardiovascular events occurred.

Factors likely to affect the results, such as , smoking, alcohol intake, history of various chronic illnesses and use of certain other medications, were taken into account.

Overall, the researchers found that patients taking the sodium-containing effervescent, dispersible and soluble medications had a 16% increased risk of a heart attack, stroke or vascular death compared with other patients taking the non-sodium versions of those exact medications .

Patients taking the sodium-containing drugs were also seven times more likely to develop high blood pressure and overall death rates were also 28% higher in this group. These events are largely driven by an increased risk of hypertension and stroke.

The authors acknowledge that there is still some controversy regarding the relation between and cardiovascular events, but say their findings "are potentially of public health importance."

They conclude: "Prescription of these -containing formulations should be done with caution, and prescribed them should be closely monitored for the emergence of hypertension."

More information: www.bmj.com/cgi/doi/10.1136/bmj.f6954

add to favorites email to friend print save as pdf

Related Stories

New study calls sodium intake guidelines into question

Nov 22, 2011

For years doctors have warned that too much salt is bad for your heart. Now a new McMaster University study suggests that both high and low levels of salt intake may put people with heart disease or diabetes at increased ...

Recommended for you

Determine patient preferences by means of conjoint analysis

1 hour ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments